fiscal year AnnualReport

fiscal year AnnualReport

fiscal year Table ofcontents Letter From Leadership...3 AABB s Mission, Vision and Core Values...4 Membership Demographics...5 FY 2013 Association Accomplishments...6 National Blood Foundation...9 AABB Board of Directors (2012-2013)... 10 A Look Ahead: AABB s Strategic Goal Statements...11 FY 2013 Financial Highlights...12 2

fiscal year Letter From Leadership Many forces are reshaping the transfusion medicine and cellular therapy field for patients, donors, blood centers, hospitals, academia and industry. We are very proud of the adaptations and investments AABB has made to support its members and customers in this changing landscape. The past 12 months demonstrates AABB s ability to keep pace with the changing times to ensure that the individuals and institutions we serve can continue to provide the highest level of quality care to patients and donors. Most notably, in fiscal year 2013, we strengthened the organizational structure of the AABB Center for Cellular Therapies by hiring Naynesh Kamani, MD, an accomplished physician scientist with clinical research experience in hematopoietic stem cell transplantation and clinical translational research. We also furthered our patient blood management, or PBM, program through the leadership provided by members of the AABB PBM Standards Program Unit and other key external stakeholders and partners. We created the Transfusion Safety and PBM subsection offering an opportunity for transfusion safety officers and other clinicians and program leaders to collaborate on the development of a multidisciplinary approach to optimizing the care of patients who might need a transfusion. This section is thriving with more than 190 individuals participating. Additionally, we moved forward with our recipient and donor hemovigilance programs and addressed regulatory developments. AABB s success in bringing together experts and thought leaders resulted in the U.S. Food and Drug Administration s recognition of the Abbreviated Blood Donor History Questionnaire, Version 1.3, that was prepared by the AABB Donor History Task Force, as well as the development of new and updated emerging infectious disease fact sheets by the AABB Transfusion Transmitted Diseases Committee. AABB also convened workshops designed to receive critical feedback from our members and key constituents to shape the association s policies and standards, including one focusing on transfusion-related acute lung injury. Through effective advocacy and our education offerings, AABB provides leading-edge information, access to expert knowledge and dissemination of best practices. The accomplishments documented in this report exhibit our commitment to the care and safety of patients and donors. Sincerely, Graham Sher, MD, PhD President-Elect Miriam A. Markowitz Chief Executive Officer 3

AABB s Mission, Vision and Core Values fiscal year Mission AABB advances the practice and standards of transfusion medicine and cellular therapies to optimize patient and donor care and safety. Vision AABB will be the pre-eminent knowledge-based organization focused on improving health through advancing the science and practice of transfusion medicine and cellular therapies. Core Values AABB will fulfill its mission and vision through adherence to its core values: the pursuit of excellence focus on the patient and donor integrity transparency consensus building innovation FACTS & FIGURES Accreditation Statistics: AABB has approximately 800 active volunteer assessors AABB assessors come from 13 countries AABB s accreditation program and assessor training program were reaccredited in FY 2013 for four years by the International Society for Quality in Health Care AABB accredited facilities are located in 29 countries 4

fiscal year Membership Demographics Statistics for Fiscal Year 2013 (Oct. 1, 2012 through Sept. 30, 2013) AABB Individual Members: 5,680 Health Care Professionals 1,561 Physicians 213 Residents 157 e-members 294 Emeritus Members AABB Institutional Members: 869 Transfusion Services 210 Blood Centers 217 Hospital Blood Banks 164 Specialty Facilities 69 Affiliates/Corporate Affiliates FACTS & FIGURES Number of countries (outside of U.S.) visited by AABB s staff and assessors for professional purposes in FY 2013 = 33+ Angola Argentina Belgium Botswana Brazil Canada China Colombia Cyprus Dominican Republic Greece Honduras Hong Kong India Italy Japan Lesotho Malawi Mauritius Mozambique Netherlands Philippines Poland Rwanda Saudi Arabia Singapore South Africa Swaziland Switzerland Taiwan Tanzania United Kingdom Zimbabwe FACTS & FIGURES TRANSFUSION Statistics: Renewal rate (includes members and nonmembers) was 95% Full-article downloads were 449,708, an increase of 6.4% Readership in China increased 26% www.transfusion.org page views were 1,556,627 More than 55% of articles were from non-u.s. authors individuals from Australia, Canada, France, Germany and United Kingdom account for the most non-u.s. contributors 5

FY 2013 Association Accomplishments fiscal year During the past 12 months, AABB has made great strides to further enhance its mission, especially with regard to its key strategic initiatives patient blood management, or PBM, cellular therapies, or CT, and hemovigilance. These initiatives are designed to ensure that members continue to have access to education and support services that help them provide optimal quality care to patients and donors. Patient Blood Management In pressing forward with its commitment to PBM, AABB developed new tools, programs and materials that assist members in adopting evidence-based, multidisciplinary approaches to optimizing the care of patients who might need transfusion. Standards for Patient Blood Management Programs After collecting comments in response to the posting of a PBM best practices document, AABB formed a PBM Standards Program Unit to develop standards for PBM using AABB s rigorous standard-setting process. The PBM Standards Program Unit composed of individuals with extensive clinical expertise and experience in the oversight of PBM-related activities published draft standards in a quality framework for public comment. Red Cell Guideline Data Card After publishing clinical practice guidelines in the Annals of Internal Medicine, AABB distilled the recommendations for red blood cell, or RBC, transfusion into a convenient laminated data card. This important information also appears in AABB s new PBM smartphone app. Development of clinical practice guidelines for platelet transfusion is underway. Transfusion Safety Officers and PBM Coordinators A new Transfusion Safety and PBM subsection of the Transfusion Medicine Section met for the first time at the 2012 AABB Annual Meeting. Since then, members of the section have met on a bimonthly basis to discuss the latest developments in PBM, present at conferences within the U.S., participate in creation of several educational offerings and network with PBM professionals around the world. Smartphone App AABB launched a smartphone app that provides easy access to the distilled RBC transfusion guidelines and the entire Circular of Information for the Use of Human Blood and Blood Components, as well as a file on managing suspected transfusion reactions. More content is planned to support clinicians in the field. Education AABB made available an array of educational offerings including PBM webinars, books, a preconvention physician s workshop and AABB Annual Meeting sessions. Development of online learning modules continued as well. 6

FY 2013 Association Accomplishments fiscal year Center for Cellular Therapies As with PBM, AABB is keeping pace with changes in the cellular therapies, or CT, arena to ensure that members are well-positioned to meet the challenges of the future. To accomplish this goal, AABB has broadened its scope to encompass the rapidly growing novel and regenerative cellular therapies field. AABB Center for Cellular Therapies During the last year, Naynesh Kamani, MD, joined AABB as division director of the AABB Center for Cellular Therapies. He has rich clinical and research experience in hematopoietic stem cell transplantation and already has guided efforts to help the many members engaged in the cellular therapies field. CT Regulatory Toolkit AABB issued the first in a four-part series of electronic tools intended to help CT professionals prepare documents for submission to the U.S. Food and Drug Administration. The first part of the series, Pre-IND Meeting Request and Briefing Package Templates, contains step-by-step instructions and templates to help guide users through the pre-ind submission and meeting process. (Three additional tools were released in FY 2014.) Clinical Standards AABB s sixth edition of Standards for Cellular Therapy Services now includes requirements that address clinical activities in the hematopoietic stem cell transplantation setting: patient consent, patient care, preparation for product administration, clinical outcomes reporting and other relevant aspects of clinical care. CT Webinar Series Throughout the year, convenient webinars covered a variety of relevant topics, including global compliance and policy, quality assurance and technical know-how. The recorded presentations are archived as a valuable resource. Podcast Series Members now can get their science on the go through podcasts on a wide variety of topics including compliance with standards requirements, ethical debates and the science behind testing methods and innovations. Cellular Therapies Section Members of the CT Section and its seven subsections have been collaborating to develop resources to assist their colleagues. One such project is on the electronic tracking of consumables and another involves training resources. FACTS & FIGURES Cellular Therapy Members by Credentials As of Sept. 30, 2013 None provided (25%) Technologist (47%) MD (21%) PhD (6%) RN (2%) N = 417 (Total number of CT Section members) 7

FY 2013 Association Accomplishments fiscal year Hemovigilance A third area in which AABB has made significant strides to enhance patient safety is that of biovigilance specifically hemovigilance through the AABB Center for Patient Safety and the AABB United States Donor Hemovigilance Program. AABB Center for Patient Safety The center is AABB s patient safety organization, or PSO, and collects and analyzes data about adverse reactions and incidents related to blood transfusions. An increasing number of hospitals have joined the AABB Center for Patient Safety to receive support with their internal hemovigilance activities and to participate in targeted interventions and analyses. By becoming a member, a hospital can participate in confidential benchmarking analytics and peer-to-peer discussions in support of transfusion safety and patient outcomes. Reporting and Analysis Throughout FY 2013, the AABB Center for Patient Safety worked with 50 hospitals to provide confidential hemovigilance reporting and assistance with respiratory adverse event analysis; conducted a case study validation of adverse reaction reporting; and led quarterly Safe Table meetings and conference calls to discuss concerns and solutions associated with adverse events in transfusion medicine. Also during this time period, the AABB Center for Patient Safety Newsletter was launched, with AABB s PSO membership receiving the first two issues of this quarterly e-communication. Quarterly Benchmarking Reports The AABB Patient Safety Organization released four quarterly benchmarking reports to its center members, comparing adverse reaction and incident data within the PSO. Most recent analyses have included comparisons of component wastage. AABB United States Donor Hemovigilance Program AABB continued its efforts to promote donor-centered hemovigilance as well. In the last 12 months, AABB s highly successful and engaged donor hemovigilance working group expanded to include the early-adopter blood centers that incorporated the AABB donor adverse reaction definitions and submitted 2012 data. These pioneers have a report analyzing their aggregated data in the pipeline for release in 2014. In addition to its hemovigilance-related achievements, AABB authored the United States Department of Health and Human Services 2011 National Blood Collection and Utilization Survey Report, which is available online at www.aabb.org. 8

fiscal year National Blood Foundation As part of its mission to improve health, AABB supports research through its National Blood Foundation, or NBF, program. Established in 1983, the NBF has distributed nearly $8 million to approximately 200 early-career scientists. In FY 2013 alone, the NBF awarded a total of $375,000 to five recipients. Funds are raised annually from corporations, blood centers, foundations and individuals. Recently, a study funded in part by the NBF resulted in a method to address the shortage of blood lacking the Vel blood group antigen. In addition to fostering scientific advances, NBF brings together leaders in the transfusion medicine and cellular therapy community through its annual Leadership Forum and as part of AABB s CEO Summit to address critical issues affecting the field. Membership continues to grow, with three organizations joining its Partners program in FY 2013: Canadian Blood Services, the Blood Bank of Delmarva and LIFELINE Blood Services. Additionally, Cerus Corporation has pledged to join NBF s Council on Research and Development, or CORD, program in FY 2014. The NBF also continues to see high registration numbers for its events, as well as generous corporate funding. As the foundation s membership expands, so do the scientific areas it supports. Applications regarding studies on cellular therapies have increased in number. Almost half of the grants awarded this year supported cellular therapyrelated investigations. In FY 2013, the NBF Board of Trustees added patient blood management to the categories of studies it will fund in FY 2014 that is, studies of evidence-based, multidisciplinary approaches for optimizing the care of patients who might need a transfusion. For more information on the NBF, individuals are invited to visit www.aabb.org/nbf or contact a representative at nbf@aabb.org or +1.301.215.6552. FACTS & FIGURES 2013 NBF Grant Applications Received Research Content Area 4 grants (12%) U.S. and Non-U.S. 2 grants (6%) 20 grants (59%) 10 grants (29%) 32 grants (94%) TM CT Infectious Disease Non-U.S. U.S. 9

fiscal year AABB Board of Directors 2012 2013 PRESIDENT Susan L. Stramer, PhD American Red Cross Gaithersburg, Md. PAST PRESIDENT Darrell J. Triulzi, MD Institute for Transfusion Medicine Pittsburgh, Pa. PRESIDENT-ELECT Graham Sher, MD, PhD Canadian Blood Services Ottawa, Ontario Canada VICE PRESIDENT Lynne Uhl, MD Beth Israel Deaconess Medical Center Boston, Mass. SECRETARY Donna Regan, MT(ASCP)SBB SSM Cardinal Glennon Children s Hospital St. Louis, Mo. TREASURER (FINANCE COMMITTEE CHAIR) Zbigniew Szczepiorkowski, MD, PhD, FCAP Dartmouth-Hitchcock Hospital Center Department of Pathology Lebanon, N.H. (Also served as At-Large Director position 1) AT-LARGE DIRECTORS Position 1 Zbigniew Szczepiorkowski, MD, PhD, FCAP Dartmouth-Hitchcock/ Hospital Center Lebanon, N.H. Position 2 Michael Murphy, MD, FRCP, FRCPath National Blood Service John Radcliffe Hospital United Kingdom Position 3 Beth Shaz, MD New York Blood Center New York, N.Y. Position 4 Susan Johnson, MSTM(ASCP)SBB BloodCenter of Wisconsin, Inc. Milwaukee, Wis. Position 5 Susan Roseff, MD Virginia Commonwealth University Medical Center Department of Pathology Richmond, Va. Position 6 Jeannie Callum, MD, FRCPC, CTBS Sunnybrook Health Sciences Centre Department Clinical Pathology/ Blood Bank Toronto, Ontario Canada Position 7 Joanne Becker, MD Roswell Park Cancer Institute Buffalo, N.Y. Position 8 E. Mary O Neill, MD American Red Cross Blood Services Dedham, Mass. Position 9 Nora Hirschler, MD Blood Centers of the Pacific San Francisco, Calif. 10 Position 10 David McKenna, Jr., MD University of Minnesota Molecular and Cellular Therapeutics St. Paul, Minn. TRANSFUSION MEDICINE SECTION REPRESENTATIVE (DIRECTOR) Eva Quinley, MS, MT(ASCP)SBB, CQA(ASQ) New York Blood Center New York, N.Y. CELLULAR THERAPIES SECTION REPRESENTATIVE (DIRECTOR) Doug Padley, MT(ASCP) Mayo Clinic Rochester, Minn. APPOINTED DIRECTOR Darin J. Weber, PhD Mesoblast, Inc. New York, N.Y. Jonathan Waters, MD Magee Women s Hospital of UPMC Pittsburgh, Pa. EX-OFFICIO DIRECTOR Miriam A. Markowitz CEO - AABB Bethesda, Md. (May 2013 - Present) Karen L. Shoos, JD CEO - AABB Bethesda, Md. (Retired as CEO in May 2013)

fiscal year A Look Ahead AABB s Strategic Goal Statements Health care, specifically in the U.S., is undergoing historic change. To uphold the association s rich legacy and ensure its relevance for years to come, the AABB Board of Directors, throughout FY 2013, focused on mapping AABB s strategic direction recognizing that AABB must remain agile and anticipate both the opportunities and challenges facing its membership. The AABB Board of Directors identified priorities and developed goal statements to capture this strategy. These goals align with the association s mission and pursuit of its vision. AABB Center for Cellular Therapies Position AABB as the leading professional association for standards setting, accreditation and quality management as well as the premier resource for education and regulatory information in cellular and regenerative therapies. Patient Blood Management (PBM) Position AABB as the leader in PBM for clinical professionals, health care institutions, and the broader health sector through the development of PBM-specific offerings (e.g., standards, accreditation, education, consulting, advocacy). International Focus Maximize AABB s value to international professionals, institutions and government agencies by effectively providing relevant resources and services in cellular therapies, blood banking and transfusion medicine. Community and Health Impact Position AABB to enhance its value to members and the broader community through impactful research, outcomes programs and advocacy to improve donor and patient care. Blood Banking and Transfusion Medicine AABB, through ongoing innovation, will retain its premier quality management brand with respect to standards setting, accreditation, education, regulatory and advocacy for blood banking and transfusion medicine. FACTS & FIGURES AABB Publication Statistics: 22 new or coming soon titles were added to AABB s offerings Content totaled 1,972 published pages of varying dimensions Content for these books was provided by 99 volunteer contributors AABB books are read in at least 91 countries around the world 170 digital downloads are available 11

FY 13 Financial Highlights AMERICAN ASSOCIATION OF BLOOD BANKS STATEMENTS OF FINANCIAL POSITION SEPTEMBER 30, 2013 and 2012 ASSETS 2013 2012 CURRENT ASSETS Cash and Cash Equivalents $ 210,882 $ 476,910 Accounts Receivable (Less Allowance of $46,934 and $25,220 in 2013 and 2012, Respectively) 870,435 2,151,942 Contributions Receivable, Current Portion 195,414 274,038 National Blood Exchange Accounts Receivable (Less Allowance of $28,066 and $99,713 in 2013 and 2012, Respectively) 2,708,257 2,287,571 Inventory 543,752 480,779 Deferred Costs 1,546,749 1,611,655 Prepaid Expenses and Other 219,631 286,767 Total Current Assets 6,295,120 7,569,662 CONTRIBUTIONS RECEIVABLE, Less Current Portion (Less Unamortized Discount of $1,193 and $3,321 in 2013 and 2012, Respectively) 10,807 8,679 INVESTMENTS 13,039,289 12,629,531 CERTIFICATES OF DEPOSIT - 259,750 PROPERTY AND EQUIPMENT Furniture and Equipment 2,245,000 2,039,150 Leasehold Improvements 598,619 598,619 Software 4,001,870 3,471,720 Software Development in Progress 576,001 564,259 7,421,490 6,673,748 Less: Accumulated Depreciation and Amortization (5,870,675) (5,307,156) Total Property and Equipment 1,550,815 1,366,592 OTHER ASSETS Security Deposit 47,921 47,921 Accrued Interest 19,937 28,253 Total Other Assets 67,858 76,174 Total Assets $ 20,963,889 $ 21,910,388 LIABILITIES AND NET ASSETS CURRENT LIABILITIES Accounts Payable and Accrued Expenses $ 2,119,339 $ 1,525,696 National Blood Exchange Accounts Payable 2,514,543 3,088,132 Unearned Revenue 5,847,035 6,075,316 Capital Lease 29,966 - Deferred Lease Incentive 43,603 43,603 Total Current Liabilities 10,554,486 10,732,747 OTHER LIABILITIES Capital Lease, Less Current Portion 68,178 - Deferred Rent 192,519 205,966 Deferred Lease Incentive, Less Current Portion 90,839 134,441 Total Other Liabilities 351,536 340,407 Total Liabilities 10,906,022 11,073,154 NET ASSETS Unrestricted 9,402,365 10,097,860 Temporarily Restricted 655,502 739,374 Total Net Assets 10,057,867 10,837,234 Total Liabilities and Net Assets $ 20,963,889 $ 21,910,388 12

FY 13 Financial Highlights 13

FY 13 Financial Highlights 14